Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Q2 Revenues Fall, Loss Rises

NEW YORK, July 22 (GenomeWeb News) - Compugen on Wednesday reported a sharp decline in revenues and a higher net loss for the second quarter of 2004, as it continues implementing its plan to focus on its therapeutic protein pipeline.

 

The Tel Aviv, Israel-based firm posted a net loss of $3.4 million, or $.12 per share, versus a net loss of $2.4 million, or $.09 per share, for the second quarter of 2003. Its revenues for the quarter declined to $984,000 from $2.9 million in the comparable period a year ago.

 

The results reflect Compugen's decision in the first quarter to cease marketing its LEADS bioinformatics platform and redirect its resources toward therapeutic protein discovery. The company also is in the process of divesting software product lines and reducing its efforts in tools and services. Last summer, Compugen sold its Bioaccelerator product line to Bioacceleration Ltd.

 

As of June 30, 2004, Compugen had $54.8 million in cash, cash equivalents and marketable securities.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.